GSK presents new data at the Alzheimer's Association International Conference 2024

ZOSTER-122 retrospective study presented during Featured Research Session on shingles and dementia risk Retrospective study observed statistically significant association between Shingrix vaccination and reduction of dementia risk, compared to Zostavax and Pneumovax 23, with further studies planned Abstracts from GSK collaboration with Alector provide new genetic evidence supporting the AL101 therapeutic hypothesis and phase II trial in Alzheimer's disease GSK plc (LSE/NYSE: GSK) today announced the presentation of four new abstracts at the Alzheimer’s Association International Conference (AAIC) being held in Philadelphia, PA from 28 July to 1 August 2024, contributing to early science in neurodegenerative diseases. Headline data from ZOSTER-122 Today GSK is presenting results from the ZOSTER-122 retrospective, observational matched-cohort study in adults aged 50 years and over, which examines the potential association between Shingrix (Recombinant Zoster Vaccine or RZV) vaccination and reduced risk of dementia compared to two other vaccines.1 GSK’s abstract is being presented alongside five other abstracts in a Featured Research Session on shingles and dementia risk. Tony Wood, Chief Scientific Officer, said: “The ZOSTER-122 retrospective study adds to the growing body of evidence that suggests an association between shingles vaccination and reduced risk of dementia. These are compelling early results, which we are investigating further with additional retrospective and mechanistic studies to advance the field.”2-9 Headline data show vaccination with either RZV or Zostavax (Zoster Vaccine Live or ZVL) was associated with statistically significant reductions in dementia risk compared to a control cohort vaccinated with Pneumovax 23 (PPSV23), another elective adult vaccine recommended for similar age groups: At three years: RZV was associated with a 24% reduced risk of dementia compared to PPSV23, and ZVL was associated with a 14% reduced risk compared to PPSV23. At five years: RZV was associated with a 20% reduced risk of dementia compared to PPSV23, and ZVL was associated with an 8% reduced risk compared to PPSV23. The study also shows that RZV was associated with statistically significant reductions in dementia risk compared to ZVL: At three years: RZV was associated with a 27% reduced risk of dementia compared to ZVL. At five years: RZV was associated with a 23% reduced risk of dementia compared to ZVL. A summary of ZOSTER-122 results is provided below.

The release as fetched from its publisher. gsk.com ↗